After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. | After Novartis and Roche grew their sales last year, the ...

The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...

E. Merck KG board of partners has announced the appointment of new CEOs to Merck KGaA’s executive board, aiding its ongoing ...

Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

Bio Asia 2025 will feature high-impact sessions, panel discussions, and networking opportunities, engaging thought leaders, ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Novartis’ move reflects gathering momentum ... Bodson will sit on the management board and report directly to chief executive Joe Jimenez. That’s significant because it gives the new digital ...

Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases ---- Amit Munshi ...